“ambr15 for cell culture process optimization” Webinar 3P Biopharmaceuticals and Sartorius Stedim Biotech

“ambr15 for cell culture process optimization” Webinar 3P Biopharmaceuticals and Sartorius Stedim Biotech

Did you miss our webinar about our experience using ambr® 15 with CHO-S cell line for the production of monoclonal antibodies?

High-throughput media and feed screening for cell culture process optimization with multi-parallel micro bioreactors

Watch it now!

In the development and delivery of high quality therapeutic proteins, high throughput process development tools can really accelerate early process understanding.

ambr® 15 cell culture system offers an alternative approach to shake flask or conventional benchtop bioreactors in an automated, multi-parallel, high throughput format. The system can be implemented within the Upstream process workflow to generate early process development data at the small scale with very low demands on operator time, set-up and turn around due to automation and single-use components, and improve global costs of development due to the minimum scale the equipment is designed to operate.

In this webinar Dr Marta Ruiz Guillén, USP development expert at 3P Biopharmaceuticals, and Javier Lobo, Field Marketing Manager for Sartorius Stedim Biotech in Latin America, Spain & Portugal; discuss the methods and results from performing media and feed screening evaluations in ambr® 15 with CHO-S cell line producing monoclonal antibodies and demonstrate the effectiveness of ambr 15 for rapid and robust cell culture process development.

Watch it now and learn more about the experiments performed:

  • Screening of different media
  • Evaluation of different feeds
  • Effect of supplements
  • Optimization of feed strategy

Our dedicated team of specialists will be happy to discuss any of your Biopharmaceutical Manufacturing needs. Contact us on +34 948 346 480 or email withinus@3pbio.com

Related Content

3P Biopharmaceuticals celebrates its 15th anniversary with Juan Carlos Unzué.

3P Biopharmaceuticals, a Navarre company founded in 2007, met with 370 employees in an exciting and joyful event looking back over its 15 years of trajectory.
Read more

3P Biopharmaceuticals and Biosergen complete together the manufacture of biomass for the Mucormycosis “Black Fungus” clinical phase II trial.

3P Biopharmaceuticals has completed the manufacture of BSG005 biomass planned for its client Biosergen. The client also recently announced Phase II clinical trial of BSG005 against Mucormycosis, otherwise known as the Black Fungus.
Read more

Regional Minister Irujo presents the Navarra Health Cluster

This morning, the Regional Minister for Economic and Business Development, Mikel Irujo, presented the Navarra Health Cluster, seeking to position the region as a European benchmark in personalized medicine, one of the priorities of the S4 Smart Specialisation Strategy. The initiative, which stems from the sector's demand and is led by a driving group, is now open to other companies and entities interested in participating.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.